Doctor concerned with health care law

Breaking news and expert analysis on legal and compliance issues

[Back To Home][Back To Archives]

From Health Law Daily, July 15, 2013

FDA provides examples of actions that constitute delay, denial, limitation or refusal of inspection leading to adulterated drug products

By Anthony H. Nguyen, JD

The FDA issued a draft guidance titled “Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug Inspection” providing examples of circumstances that the agency would consider to constitute delaying, denying, or limiting inspection, or refusing to permit entry or inspection (Notice, 78 FR 42387, July 15, 2013). Facilities found to have performed any of the actions described in the draft document would have their products deemed adulterated under FDA regulations.

Background. The Food and Drug Administration Safety and Innovation Act (FDASIA) added a new provision to the Food, Drug, and Cosmetic Act (FDC Act) regarding inspections that would make a drug adulterated. Under 21 U.S.C. 351(j), the FDA is required within one year of the enactment of FDASIA to issue a guidance defining the circumstances constituting a delay, denial, or limitation of an inspection, as well as address the refusal to permit entry or inspection.

Guidance information. The FDA did not interpret the four terms describing prohibited behavior in the draft guidance (delay, deny, limit, refuse) as mutually exclusive. Examples of delay in scheduling a pre-announced inspection that may cause drugs to be considered as adulterated include, but were not limited to: (1) a facility not agreeing to a proposed inspection start date and failing to provide a reasonable explanation for its failure to do so; (2) after scheduling an inspection, a facility failing to request a later start date without giving a reasonable explanation; or (3) failing to respond following the FDA’s attempt to contact the facility’s designated contact(s).

Limiting access to photography or copying of records would be considered by the agency as a limitation on inspection. Additionally, during an inspection, not permitting the FDA investigator access to an area until a specific future date or time, leaving the FDA investigator without access to necessary documentation or responsible individuals for unreasonable periods of time, or failing to produce records in a reasonable timeframe would constitute a delay that may cause a drug to be considered adulterated.

The FDA also addressed various denials or refusals of inspection, including but not limited to: (1) rejecting attempts to schedule an inspection; (2) refusing to permit the commencement of a pre-scheduled inspection: (3) refusing inspection until certain staff is present; or (4) falsely alleging that the facility did not manufacture drugs.

MainStory: TopStory AdulterationNews DrugBiologicalNews

Health Law Daily

Introducing Wolters Kluwer Health Law Daily — a daily reporting service created by attorneys, for attorneys — providing same-day coverage of breaking news, court decisions, legislation, and regulatory activity.

A complete daily report of the news that affects your world

  • View full summaries of federal and state court decisions.
  • Access full text of legislative and regulatory developments.
  • Customize your daily email by topic and/or jurisdiction.
  • Search archives for stories of interest.

Not just news — the right news

  • Get expert analysis written by subject matter specialists—created by attorneys for attorneys.
  • Track law firms and organizations in the headlines with our new “Who’s in the News” feature.
  • Promote your firm with our new reprint policy.

24/7 access for a 24/7 world

  • Forward information with special copyright permissions, encouraging collaboration between counsel and colleagues.
  • Save time with mobile apps for your BlackBerry, iPhone, iPad, Android, or Kindle.
  • Access all links from any mobile device without being prompted for user name and password.